Skip to main content

Table 3 Relative weight of shared component between adjuvant therapies for separate cohort model adjusted for all other predictor variables

From: Geographic variation in the intended choice of adjuvant treatments for women diagnosed with screen-detected breast cancer in Queensland

  Median posterior relative weights [95 % CrIa]
  Radiotherapy Chemotherapy Hormonal therapy
At age 40–49    
Radiotherapy 1.00
Chemotherapy 0.57 [0.31, 0.94] 1.00
Hormonal therapy 0.86 [0.57, 1.29] 1.51 [0.92, 2.66] 1.00
At age 50–59    
Radiotherapy 1.00
Chemotherapy 0.40 [0.23, 0.65] 1.00
Hormonal therapy 0.87 [0.63, 1.19] 2.16 [1.36, 3.63] 1.00
At age 60–69    
Radiotherapy 1.00
Chemotherapy 0.58 [0.31, 0.95] 1.00
Hormonal therapy 0.81 [0.58, 1.11] 1.39 [0.84, 2.62] 1.00
At age 70–89    
Radiotherapy 1.00
Chemotherapy 0.92 [0.48, 1.55] 1.00
Hormonal therapy 0.74 [0.50, 1.08] 0.80 [0.48, 1.55] 1.00
Localised tumour    
Radiotherapy 1.00
Chemotherapy 0.34 [0.18, 0.58] 1.00
Hormonal therapy 0.81 [0.61, 1.05] 2.42 [1.39, 4.47] 1.00
Advanced tumour    
Radiotherapy 1.00
Chemotherapy 0.86 [0.63, 1.18] 1.00
Hormonal therapy 0.86 [0.61, 1.17] 0.99 [0.72, 1.41] 1.00
  1. aCredible interval